Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
Conditions
Keywords
Leukemia, Lymphoma, Multiple Myeloma, Bone Marrow Transplantation, Immune Therapy
Brief summary
Background: Patients with cancers of the blood and immune system often benefit from transplants of stem cells from a genetically well-matched sibling. However, severe problems may follow these transplants because of the high-dose chemotherapy and radiation that accompany the procedure. Also, donated immune cells sometimes attack healthy tissues in a reaction called graft-versus-host disease (GVHD), damaging organs such as the liver, intestines and skin. To reduce toxicity of high-dose preparative chemotherapy, this study performs allogeneic transplant after low doses of chemotherapy. In an attempt to improve anti-tumor effects without increasing GVHD, this study uses donor immune cells (T helper 2 (Th2) cells) grown in the laboratory; some patients will receive standard donor immune cells (not grown in laboratory). All patients will receive immune modulating drugs sirolimus and cyclosporine to prevent GVHD. Objective: To determine the safety, treatment effects and rate of GVHD in patients receiving transplants that use low-intensity chemotherapy, sirolimus plus cyclosporine, and transplant booster with either Th2 cells or standard immune cells. Eligibility: Patients 16 to 75 years of age with acute or chronic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, or myelodysplastic syndrome. Patients must have a suitable genetically matched sibling donor and adequate kidney, heart and lung function. Design: The protocol has three treatment groups: cohort 1, Th2 booster at two weeks post-transplant; cohort 2, standard T cell booster at two weeks post-transplant; cohort 3, multiple infusion of Th2 cells. Condition: Hematologic Neoplasms, Myeloproliferative Disorders Intervention: Biological; therapeutic allogeneic lymphocytes Drug: Sirolimus Study Type: Interventional Study Design: Primary Purpose: Treatment Phase: Phase II
Detailed description
Background In protocol 99-C-0143, we evaluated a new approach to allogeneic hematopoietic stem cell transplant (HSCT) that involved intensive host T cell ablation and graft augmentation with in vitro generated donor T helper 2 (Th2) cells. Rapid full donor engraftment occurred with this regimen; however, grade II to IV acute graft versus host disease (GVHD) was not significantly reduced in Th2 cell recipients. In an attempt to improve clinical results using Th2 cell graft engineering, this second-generation Th2 cell clinical trial was developed that incorporates the following interventions: (1) In an attempt to reduce transplant-related toxicity, this protocol now uses a very low-intensity host preparative chemotherapy; (2) In an attempt to reduce GVHD, this study will utilize Th2 cells expanded in the presence of the immune modulation agent, rapamycin (sirolimus), as murine Th2 cells grown in rapamycin reduce GVHD more effectively than control Th2 cells; (3) To further reduce GVHD, subjects will receive a short-course of sirolimus therapy in addition to standard cyclosporine GVHD prophylaxis; and (4) Using this novel low-intensity transplant platform, compare in a preliminary manner the post-transplant outcome of patients receiving pre-emptive donor lymphocyte infusion (DLI) using either Th2 cells or unmanipulated donor T cells. Objectives In the setting of human leukocyte antigen (HLA)-matched sibling allogeneic HSCT using GVHD prophylaxis of cyclosporine and short-course sirolimus, compare in a preliminary manner the safety, feasibility, alloengraftment, clinical anti-tumor effects, and GVHD rate of low-intensity Preparative Chemotherapy with pre-emptive DLI using either Th2 cells or unmanipulated T cells at day 14 post-HSCT. Eligibility Subjects that are 16 to 75 years of age that have a suitable 6/6 HLA-matched sibling donor are potentially eligible. Subjects with a diagnosis of acute or chronic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, or myelodysplastic syndrome are potentially eligible. Adequate kidney, cardiac, and pulmonary function are required. Design * Patients age 18 or older with lymphoma (all types) or chronic lymphocytic leukemia will be randomized just prior to the transplant regimen to receive DLI with either donor Th2 cells (cohort 1) or unmanipulated T cells (cohort 2); n=10 patients will be accrued to each arm provided that stopping rules pertaining to excessive GVHD or graft rejection are not met. For these randomized patients, the preparative regimen will consist of low-intensity fludarabine (120 mg/m(2)) plus cyclophosphamide (1200 mg/m(2)) and GVHD prophylaxis will consist of short-course, high-dose sirolimus followed by maintenance cyclosporine. Cohorts 1 and 2 will be compared in a preliminary manner with respect to their post-transplant outcome, in particular: (a) conversion of mixed chimerism to predominant donor chimerism; (b) rate and severity of classical acute and late acute GVHD at the day 100 and day 180 post-transplant time points; and (c) time to induction of leukemia/lymphoma remission (if entering transplant with disease) or time to relapse (if entering transplant in remission). * Patients with non-lymphoma diagnoses, patients with lymphoma that are under the age of 18 and lymphoma patients that are projected to be unable to complete the protocol-defined therapy through day 180 post-transplant will not be randomized but will be treated on cohort 3 (n=40), which will evaluate transplantation without the Flu/Cy preparative regimen and with pre-emptive Th2 cell DLI. The primary objective of cohort 3 is to evaluate whether transplantation without a preparative regimen will reduce the rate of acute GVHD associated with Th2 cell DLI from 41% (the rate observed with the fludarabine/cyclophosphamide (Flu/Cy) preparative regimen) to a rate of 15% (6 cases out of 40).
Interventions
DRUGRituximab
Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).
DRUGFludarabine
Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
DRUGEtoposide
Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.
DRUGDoxorubicin
Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
DRUGVincristine
Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.
DRUGCyclophosphamide
Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
PROCEDUREPeripheral blood stem cell (PBSC) transplantation
PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.
GENETICT cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).
DRUGPrednisone
Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
Allogeneic Hematopoietic Stem Cell Transplant.
DRUGFilgrastim
Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).
GENETICT-Rapa cell Donor Lymphocyte Infusion (DLI)
The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
11 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* INCLUSION CRITERIA: PATIENT RECIPIENT 1. Patients with hematologic malignancies, myelodysplasia, or myeloproliferative disorders, as summarized in the following table. The diagnosis must be histologically confirmed by the Laboratory of Pathology of National Cancer Institute (NCI) or Hackensack (There will be no central pathology review). 2. Chronic Lymphocytic Leukemia - Disease Status: a) Relapse post-fludarabine, b) Non-Complete Response (CR) after salvage regimen. Hodgkin's and Non-Hodgkin's Lymphoma (all types, including Mantle Cell Lymphoma) - Disease Status: a) Primary treatment failure, b) Relapse after autologous stem cell transplant (SCT), c) Non-CR after salvage regimen Special Cases of High-Risk Lymphoma, including but not limited to : (1) plasma dendritic cell type, 2) Hepato-splenic T cell type, 3) gamma delta pinniculitic T cell type, 4) Muco-cutaneous natural killer (NK) cell type and 5) stage III-IV nasal NK cell type- Disease Status: a) Primary treatment failure, b) Relapse after autologous, c) Non-CR after salvage regimen, d) In first CR or any later CR Chronic Epstein Barr Virus (EBV)-associated lymphoproliferative disease a) At any point after diagnosis, including up-front therapy Multiple Myeloma - Disease Status: a) Primary treatment failure, b) Relapse after autologous stem cell transplant (SCT), c) Non-CR after salvage regimen. Acute Myelogenous Leukemia - Disease Status: a) CR number 1 and high-risk \[excludes t(8;21), t(15;17), or inv(16)\], b) CR number 2 or greater). Acute Lymphocytic Leukemia - Disease Status: a) CR number 1 plus high-risk \[t(9;22) or bcr-abl(+); t(4;11), 1(1;19), t(8;14)\], b) In CR number2 or greater. Myelodysplastic Syndrome - Disease Status: a) Refractory Anemia with Excess Blasts (RAEB), b) Refractory Anemia with Excess Blasts in Transformation (RAEB-T) (requires marrow and blood blasts less than 10% after induction chemotherapy). Myeloproliferative disorders - Disease Status: a) Idiopathic myelofibrosis, b) Polycythemia vera, c) Essential thrombocytosis, d) Chronic myelomonocytic leukemia. Chronic Myelogenous Leukemia (CML) - Disease Status: a) Chronic phase CML, refractory to imatinib treatment b) Accelerated phase CML. b) Accelerated phase CML Patients with myeloproliferative disorders must be end-stage, which is primarily defined as disease severity refractory to splenectomy. 3. Patient age of 16 to 75 years. 4. Consenting first degree relative matched at 6/6 HLA antigens (A, B, and DR). 5. Patient or legal guardian must be able to give informed consent. 6. All previous intravenous therapy administered outside of the National Institutes of Health (NIH) Clinical Center must be completed at least 2 weeks prior to study entry, with recovery to less than or equal to non-hematologic grade 2 toxicity of previous therapy. 7. Eastern Cooperative Oncology Group (ECOG) performance status equal to 0 or 1. 8. Life expectancy of at least 3 months. 9. Patients with acute leukemia must have chemotherapy sensitive disease, as defined by at least a 50% reduction in circulating absolute blast count due to the most proximal regimen. 10. Left ventricular ejection fraction greater than or equal to 45%, preferably by 2-dimension (2-D) echo, or by multi-gated acquisition scan (MUGA). However, patients with left ventricular ejection fraction (LVEF) of between 35% and 44% may also be eligible provided that such patients are cleared by a Cardiology Consultation that must include a cardiac stress test. 11. Corrected diffusing capacity or transfer of the lung for carbon monoxide (DLCO) greater than 50% of expected value. 12. Creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than or equal to 50 ml/min. 13. Serum total bilirubin less than 2.5 mg/dl; serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) equal 2.5 times upper limit of normal. Values above these levels may be accepted, at the discretion of the principal investigator (PI) or study chairman, if such elevations are thought to be due to liver involvement by malignancy or graft versus host disease (GVHD). 14. Adequate central venous access potential. 15. Potential patients referred for the study may not be eligible for the experimental protocol therapy due to reasons such as uncertainty about donor human leukocyte antigen (HLA) typing or need to control malignant disease, infection, or metabolic abnormality such as hypercalcemia on a emergent basis. Should a referred patient present to us in such a scenario, the patient will be referred back to their primary hematologist-oncologist for treatment. However, if referral back to the referring physician is not in the best interest of the patient according to the clinical judgement of the principal investigator (PI), then the patient may receive standard treatment for the malignant disease or complicating conditions (infection, metabolic problems under the current study. In other cases, a patient may have reasonable control of malignancy but does not meet the cluster of differentiation 4 (CD4) cell cut-off of 50 cells per microliter required for cohort 3 therapy; in such cases, standard care chemotherapy regimens may be administered for the specific goal of reducing the CD4 count (that is, immune depleting regimens such as the pentostatin plus cyclophosphamide combination, administered similar to the manner that we have developed on protocol 08-C- 0088). If it becomes apparent that the patient will not be able to proceed to experimental therapy, then he/she must come off study. Recipient-Subjects receiving a standard therapy, and availability of receiving the same treatment elsewhere, outside of a research protocol. Because such standard care therapy is not experimental, it is not necessary to complete the eligibility criteria prior to receiving such standard care; however, prior to initiation of the experimental therapy, the patient must meet each of the eligibility criteria detailed above. Attempts will be made to standardize such pretransplant chemotherapy (by administration of etoposide, prednisolone, oncovin, cyclophosphamide, hydroxydaunorubicin, fludarabine, rituximab (EPOCH-FR) chemotherapy, which is detailed later in this protocol); however, other regimens using approved agents will be allowed if such regimens are thought to be in the best interest of the patient. INCLUSION CRITERIA: DONOR 1. First-degree relative with genotypic identity at 6/6 HLA loci (HLA- A, B, and DR). 2. Age 11 to 90 years and able to give consent or assent. For donors \< 18 years old, the legal guardian must be able to provide informed consent. 3. Adequate venous access for peripheral apheresis, or consent to use a temporary central venous catheter for apheresis. 4. Donors must be human immunodeficiency virus (HIV) negative. 5. Donors with a history of hepatitis B or hepatitis C infection may be eligible. However, eligibility determination of such patients will require a hepatology consultation. The risk/benefit of the transplant and the possibility of transmitting hepatitis will be discussed with the patient and eligibility will then be determined by the principal investigator and lead associate investigator (LAI). 6. Lactating donors must substitute formula feeding for her infant during period of filgrastim administration (to prevent any filgrastim effect on infant).
Exclusion criteria
PATIENT 1. Active infection that is not responding to antimicrobial therapy. 2. Active central nervous system (CNS) involvement by malignancy. 3. HIV infection (treatment may result in progression of HIV and other viral infections). 4. Chronic active hepatitis B. Patient may be hepatitis B core antibody positive. For patients with concomitant positive hepatitis B surface antigen, patient will require a hepatology consultation. The risk/benefit profile of transplant and hepatitis B will be discussed with the patient and eligibility determined by the principal investigator and Lead Associate Investigator. 5. Hepatitis C infection. Patient may have hepatitis C infection. However, each patient will require a hepatology consultation. The risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and Lead Associate Investigator. 6. Pregnant or lactating. Patients of childbearing potential must use an effective method of contraception. The effects of the chemotherapy, the subsequent transplant and the medications used after the transplant are highly likely to be harmful to a fetus. The effects upon breast milk are also unknown and may be harmful to the infant. 7. History of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients to Receive T Cell Infusion | first 100 days post-transplant | T cells administered by intravenous infusion after patient received transplant. |
| Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD) | first 100 days post-transplant | GVHD of the skin, liver and gut were graded on a scale of 1, 2, 3, and 4 (e.g. the grades are not added together) using the National Institutes of Health Consensus Criteria. Grade 1 is minimal GVHD, Grade 2 is moderate GVHD, Grade 3 is severe GVHD and Grade 4 is very severe GVHD. Grade 4 is a worse outcome than Grade 1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Detection of of Post-transplantation Cluster of Differentiation 4 (CD4)+ and CD8+ T-cell Production of T Helper 1 -2 (Th1-Th2)-Type Cytokines | First 100 days post-transplant | Detection of cytokine secretion was done by enzyme-linked immunosorbent assay. |
| Percentage of Patients With Opportunistic Infection | First 100 days post-transplant | Participants are susceptible to opportunistic infections such as bacterial, fungal, viral, protozoan infections and more due to immune suppression from chemotherapy drugs used to treat their disease. |
| Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0) | Date treatment consent signed to date off study, approximately 5 years | Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
Countries
United States
Participant flow
Pre-assignment details
Enrollment was 442 (221 donors; 221 patients). 57 recipients were treated on cohorts no longer in the protocol due to amendments. Thus, 164 of 221 recipient data is presented. No patients were eligible for therapy on arm IVD, cohort 2.
Participants by arm
| Arm | Count |
|---|---|
| Arm IVDcohort 1 (Th2 DLI) Patients receive low intensity fludarabine phosphate intravenous (IV) and cyclophosphamide IV on days -6 to -3. Patients undergo donor lymphocyte infusion (DLI) with sirolimus generated donor T-helper 2 (Th2) cells on day 14 (single T-Rapa cell DLI in patients with cluster of differentiation 4 (CD4) count between 100 and 200 inclusive). | 1 |
| Arm IVD Cohort 3 (Multiple Th2 DLI) Patients with nonlymphoma diagnosis or rapidly progressive lymphoma undergo DLI with multiple infusions of sirolimus generated donor Th2 cells beginning on day 14 (multiple T-Rapa cell DLI in patients with CD4 count lower than 100 or ALC lower than 300). | 34 |
| Arm IVA (12-day Expanded Th2 DLI) Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine by mouth twice a day (PO BID) on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic peripheral blood stem cells (PBSC) on day 0. Patients undergo DLI with 12-day expanded sirolimus-generated donor Th2 cells on day 14. | 40 |
| Arm IVB (6-day Expanded Th2 DLI) Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14. | 44 |
| Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7, Patients undergo mobilized allogeneic PBSC on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14. | 45 |
| Total | 164 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Progressive malignancy | 0 | 7 | 0 | 0 | 3 | 0 |
Baseline characteristics
| Characteristic | Arm IVDcohort 1 (Th2 DLI) | Arm IVD Cohort 3 (Multiple Th2 DLI) | Arm IVA (12-day Expanded Th2 DLI) | Arm IVB (6-day Expanded Th2 DLI) | Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) | Total |
|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 1 Participants | 4 Participants | 3 Participants | 3 Participants | 11 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants | 33 Participants | 36 Participants | 41 Participants | 42 Participants | 153 Participants |
| Age, Continuous | 56 years | 45.96 years STANDARD_DEVIATION 12.41 | 49.68 years STANDARD_DEVIATION 12.92 | 47.66 years STANDARD_DEVIATION 12.45 | 50.19 years STANDARD_DEVIATION 13.5 | 49.44 years STANDARD_DEVIATION 13.12 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 11 Participants | 8 Participants | 10 Participants | 4 Participants | 33 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 23 Participants | 32 Participants | 34 Participants | 41 Participants | 131 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 0 Participants | 2 Participants | 1 Participants | 5 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 4 Participants | 2 Participants | 4 Participants | 11 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 11 Participants | 8 Participants | 10 Participants | 4 Participants | 33 Participants |
| Race (NIH/OMB) White | 1 Participants | 20 Participants | 28 Participants | 30 Participants | 36 Participants | 115 Participants |
| Region of Enrollment United States | 1 Participants | 34 Participants | 40 Participants | 44 Participants | 45 Participants | 164 Participants |
| Sex: Female, Male Female | 0 Participants | 8 Participants | 17 Participants | 21 Participants | 13 Participants | 59 Participants |
| Sex: Female, Male Male | 1 Participants | 26 Participants | 23 Participants | 23 Participants | 32 Participants | 105 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 1 | 14 / 34 | 22 / 40 | 24 / 44 | 22 / 45 |
| other Total, other adverse events | 1 / 1 | 28 / 34 | 40 / 40 | 38 / 44 | 36 / 45 |
| serious Total, serious adverse events | 1 / 1 | 22 / 34 | 37 / 40 | 35 / 44 | 31 / 45 |
Outcome results
Primary
Percentage of Patients to Receive T Cell Infusion
T cells administered by intravenous infusion after patient received transplant.
Time frame: first 100 days post-transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm IVD Cohort 1 (Th2 DLI) | Percentage of Patients to Receive T Cell Infusion | 100 percentage of patients |
| Arm IVD Cohort 3 (Multiple Th2 DLI) | Percentage of Patients to Receive T Cell Infusion | 100 percentage of patients |
| Arm IVA (12-day Expanded Th2 DLI) | Percentage of Patients to Receive T Cell Infusion | 100 percentage of patients |
| Arm IVB (6-day Expanded Th2 DLI) | Percentage of Patients to Receive T Cell Infusion | 100 percentage of patients |
| Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) | Percentage of Patients to Receive T Cell Infusion | 100 percentage of patients |
Primary
Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD)
GVHD of the skin, liver and gut were graded on a scale of 1, 2, 3, and 4 (e.g. the grades are not added together) using the National Institutes of Health Consensus Criteria. Grade 1 is minimal GVHD, Grade 2 is moderate GVHD, Grade 3 is severe GVHD and Grade 4 is very severe GVHD. Grade 4 is a worse outcome than Grade 1.
Time frame: first 100 days post-transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm IVD Cohort 1 (Th2 DLI) | Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD) | 0 percentage of patients |
| Arm IVD Cohort 3 (Multiple Th2 DLI) | Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD) | 11.11 percentage of patients |
| Arm IVA (12-day Expanded Th2 DLI) | Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD) | 10 percentage of patients |
| Arm IVB (6-day Expanded Th2 DLI) | Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD) | 40.91 percentage of patients |
| Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) | Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD) | 40.48 percentage of patients |
Secondary
Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, approximately 5 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm IVD Cohort 1 (Th2 DLI) | Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0) | 1 Participants |
| Arm IVD Cohort 3 (Multiple Th2 DLI) | Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0) | 27 Participants |
| Arm IVA (12-day Expanded Th2 DLI) | Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0) | 40 Participants |
| Arm IVB (6-day Expanded Th2 DLI) | Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0) | 44 Participants |
| Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) | Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0) | 42 Participants |
Secondary
Detection of of Post-transplantation Cluster of Differentiation 4 (CD4)+ and CD8+ T-cell Production of T Helper 1 -2 (Th1-Th2)-Type Cytokines
Detection of cytokine secretion was done by enzyme-linked immunosorbent assay.
Time frame: First 100 days post-transplant
Population: This outcome measure was not done. Data was not collected for this outcome measure due to premature closure of study.
Secondary
Percentage of Patients With Opportunistic Infection
Participants are susceptible to opportunistic infections such as bacterial, fungal, viral, protozoan infections and more due to immune suppression from chemotherapy drugs used to treat their disease.
Time frame: First 100 days post-transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm IVD Cohort 1 (Th2 DLI) | Percentage of Patients With Opportunistic Infection | 0 percentage of participants |
| Arm IVD Cohort 3 (Multiple Th2 DLI) | Percentage of Patients With Opportunistic Infection | 11.11 percentage of participants |
| Arm IVA (12-day Expanded Th2 DLI) | Percentage of Patients With Opportunistic Infection | 7.50 percentage of participants |
| Arm IVB (6-day Expanded Th2 DLI) | Percentage of Patients With Opportunistic Infection | 9.09 percentage of participants |
| Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) | Percentage of Patients With Opportunistic Infection | 11.90 percentage of participants |